Literature DB >> 14747572

Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Bindong Liu1, Xianghui Yu, Kun Luo, Yunkai Yu, Xiao-Fang Yu.   

Abstract

The Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for viral evasion of the host antiviral protein APOBEC3G, also known as CEM15. Vif mutant but not wild-type HIV-1 viruses produced in the presence of APOBEC3G have been shown to undergo hypermutations in newly synthesized viral DNA upon infection of target cells, presumably resulting from C-to-U modification during minus-strand viral DNA synthesis. We now report that HIV-1 Vif could induce rapid degradation of human APOBEC3G that was blocked by the proteasome inhibitor MG132. The efficiency of Vif-induced downregulation of APOBEC3G expression depended on the level of Vif expression. A single amino acid substitution in the conserved SLQXLA motif reduced Vif function. Vif proteins from distantly related primate lentiviruses such as SIVagm were unable to suppress the antiviral activity of human APOBEC3G or the packaging of APOBEC3G into HIV-1 Vif mutant virions, due to a lack of interaction with human APOBEC3G. In the presence of the proteasome inhibitor MG132, virion-associated Vif increased dramatically. However, increased virion packaging of Vif did not prevent virion packaging of APOBEC3G when proteasome function was impaired, and the infectivity of these virions was significantly reduced. These results suggest that Vif function is required during virus assembly to remove APOBEC3G from packaging into released virions. Once packaged, virion-associated Vif could not efficiently block the antiviral activity of APOBEC3G.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747572      PMCID: PMC369424          DOI: 10.1128/jvi.78.4.2072-2081.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Evidence for a newly discovered cellular anti-HIV-1 phenotype.

Authors:  J H Simon; N C Gaddis; R A Fouchier; M H Malim
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

2.  Feline immunodeficiency virus Vif localizes to the nucleus.

Authors:  U Chatterji; C K Grant; J H Elder
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.

Authors:  G Dornadula; S Yang; R J Pomerantz; H Zhang
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.

Authors:  H Zhang; R J Pomerantz; G Dornadula; Y Sun
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.

Authors:  M Dettenhofer; S Cen; B A Carlson; L Kleiman; X F Yu
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.

Authors:  K M Lockridge; M Chien; G A Dean; K Stefano Cole; R C Montelaro; P A Luciw; E E Sparger
Journal:  Virology       Date:  2000-07-20       Impact factor: 3.616

7.  Role of Vif in stability of the human immunodeficiency virus type 1 core.

Authors:  A Ohagen; D Gabuzda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.

Authors:  U Schubert; D E Ott; E N Chertova; R Welker; U Tessmer; M F Princiotta; J R Bennink; H G Krausslich; J W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

9.  Subcellular localization of the Vif protein of human immunodeficiency virus type 1.

Authors:  J Goncalves; P Jallepalli; D H Gabuzda
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  74 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

Review 3.  Retroviruses under editing crossfire: a second member of the human APOBEC3 family is a Vif-blockable innate antiretroviral factor.

Authors:  Didier Trono
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

4.  APOBEC3G incorporation into human immunodeficiency virus type 1 particles.

Authors:  Véronique Zennou; David Perez-Caballero; Heinrich Göttlinger; Paul D Bieniasz
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

6.  Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.

Authors:  Kun Luo; Zuoxiang Xiao; Elana Ehrlich; Yunkai Yu; Bindong Liu; Shu Zheng; Xiao-Fang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

7.  Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.

Authors:  Yunkai Yu; Zuoxiang Xiao; Elana S Ehrlich; Xianghui Yu; Xiao-Fang Yu
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

8.  Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.

Authors:  Guylaine Haché; Truus E M Abbink; Ben Berkhout; Reuben S Harris
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 9.  Curing HIV: lessons from cancer therapy.

Authors:  Ronald Mitsuyasu
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

10.  HIV-1 Vif and APOBEC3G: multiple roads to one goal.

Authors:  Joao Goncalves; Mariana Santa-Marta
Journal:  Retrovirology       Date:  2004-09-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.